Can you target specific muscle types, such as the myocardium?

Yes, we offer specialized Cardiac Muscle Homing services where the phage recovery is focused exclusively on the heart tissue, including counter-selection against skeletal muscle.

How do you ensure the peptides identified are not just binding to the blood vessels within the muscle?

We use a rigorous systemic perfusion protocol with saline or PBS before tissue harvesting to wash away phages that are loosely associated with the endothelium or still in the blood.

What is the advantage of using NGS over traditional Sanger sequencing for phage display?

NGS allows us to analyze millions of sequences, enabling us to see the "enrichment trajectory" of a clone across rounds, even if it is not the dominant clone, often revealing highly specific but lower-abundance binders.

Can the identified peptides be used for AAV capsid engineering?

Absolutely. Many of our clients use the peptides discovered through our in vivo screening to modify the loops of AAV capsids for muscle-tropic gene therapy.

Are the peptides discovered stable in human serum?

While screening is done in animal models, we provide downstream peptide modification services (e.g., D-amino acid substitution or cyclization) to enhance proteolytic stability for human applications.

What quantity of phage library is injected?

Generally, we inject 10 11 to 10 13 plaque-forming units (pfu) to ensure adequate coverage of the library's diversity within the animal's circulation.

Does Creative Biolabs provide help with the functional validation of the hits?

Yes, we offer in vitro binding assays (ELISA, Flow Cytometry) and in vivo biodistribution studies using labeled peptides to confirm the screening results.

What animal models are available for muscle targeting screening?

We primarily use mice and specialized disease models like mdx mice for DMD. Large animal models (e.g., rabbits or non-human primates) can be accommodated upon request.

How many rounds of biopanning are typically required?

Usually 3 to 4 rounds. This allows for sufficient enrichment of specific binders while maintaining the diversity of potential lead candidates.

Is NGS mandatory for this service?

While optional, we highly recommend it. NGS provides a much deeper view of the library's evolution and can identify potent peptides that might be missed by traditional colony picking.

What is the typical length of the peptides in your libraries?

Our standard libraries display 7-mer to 12-mer peptides. Longer or constrained (cyclic) peptides are also available.

Do you provide the physical phage clones at the end of the project?

Yes, we provide the enriched library pool, individual validated clones, and a comprehensive sequencing report.

How do you validate the "tissue-penetrating" ability?

We use a combination of microdialysis-based recovery and immunofluorescence microscopy to confirm that the phages have moved from the vasculature into the extravascular muscle tissue.

In Vivo Phage Library Screening Service for Muscle Targeting

Background Platform Workflow Specialized Strategy Advantage Related Service FAQ Online Inquiry

Skeletal and cardiac muscles constitute a significant portion of total body mass and are central to numerous metabolic and physiological functions. However, delivering therapeutic agents—ranging from small molecules to gene therapy vectors—specifically to muscle tissue remains a formidable challenge in modern biopharmaceutics. Non-specific distribution often leads to sub-therapeutic concentrations at the target site and undesired systemic side effects. Creative Biolabs, a global leader in phage display technologies with over 20 years of expertise, offers a premier Muscle Targeting In Vivo Phage Library Screening Service. By leveraging the physiological complexity of a living organism, our platform identifies high-affinity, muscle-homing peptides that can bypass biological barriers, ensuring your therapeutic payload reaches its destination with surgical precision.

Discuss Your Project Today

The Power of In Vivo Phage Display for Muscle

Unlike traditional in vitro biopanning against purified proteins or cultured cells, in vivo phage display screening captures the "real-world" interaction between the phage library and the vascular endothelium, interstitial matrix, and myocyte membranes within the functional muscle architecture.

Feature	In Vitro Screening	In Vivo (Creative Biolabs)
Microenvironment	Artificial/Simplified	Native Physiological Context
Biological Barriers	Absent (No blood flow/clearance)	Present (Reflects actual PK/PD)
Target Relevance	Isolated Antigens	Complex Multicellular Tissue
Success Rate	Moderate (May fail in animal models)	High (Pre-validated in living systems)
Specificity	High for ligand, low for tissue	Superior tissue-specific homing

Our Advanced Muscle-Targeting Platform

We utilize diverse phage libraries (M13, T7, or T4) displaying billions of unique peptide sequences (linear, cyclic, or constrained). Our proprietary Next-Gen Muscle Homing Technology (NG-MHT) integrates high-throughput screening with deep sequencing to identify candidates that others might miss.

Key Applications

Neuromuscular Disease Treatment: Targeting Duchenne Muscular Dystrophy (DMD) or Spinal Muscular Atrophy (SMA).
Cardiology: Development of cardiac-homing peptides for myocardial infarction recovery.
Metabolic Research: Modulating glucose uptake via muscle-specific ligands.
Gene Therapy: Optimization of AAV or nanoparticle tropism toward muscle tissue.

Technical Workflow of Muscle Targeting In Vivo Phage Display Screening

Our workflow is designed to maximize enrichment while minimizing "noise" from non-specific binding.

1. Library Construction and Selection

We offer a variety of high-diversity libraries (>10¹⁰ unique clones), including:

Linear peptide libraries
Cyclic peptide libraries using disulfide constraints
Tissue-penetrating peptide focused libraries

2. Systemic Administration and Circulation

The library is injected intravenously into the chosen animal model. During the circulation phase, phages interact with the muscle vasculature and cellular receptors.

3. Progressive Biopanning Strategy

Round	Focus	Objective
Round 1	Initial Capture	Broad identification of phages with muscle affinity.
Round 2	Specificity Enhancement	Increased stringency; removal of phages sequestered by the Reticuloendothelial System (RES).
Round 3	Internalization/Penetration	Selection for peptides that not only bind but enter the muscle cells (Internalizing Phage).

4. Advanced Data Analysis (NGS & Bioinformatics)

Unlike traditional plaque counting, we employ NGS-based profiling to track the enrichment of thousands of clones simultaneously, ensuring that rare but highly effective candidates are not lost.

Fig. 1 Screening for peptides aiming at muscle targeting.

Specialized Muscle Targeting Strategies at Creative Biolabs

Overcoming the "Liver Sieve" in Phage Display

One of the primary challenges in In Vivo Phage Library Screening is the natural sequestration of phages by the Reticuloendothelial System (RES), primarily the liver and spleen. At Creative Biolabs, we employ advanced "pre-adsorption" strategies where the library is first exposed to non-target tissues or circulation-blocking agents to minimize background noise. This ensures that the phages recovered from muscle are truly tissue-specific rather than just "sticky" variants.

The Role of Vascular Endothelial Heterogeneity

Muscle tissue is highly vascularized, but the endothelium of muscle capillaries is distinct from that of the brain or lungs. Our In Vivo Phage Display for Muscle targets these unique molecular "zip codes"—receptors or membrane proteins expressed specifically on the luminal surface of the muscle vasculature.

Emerging Trends: Multi-Organ Biodistribution Profiling

By utilizing AI-assisted bioinformatics, we can now provide a "heat map" of peptide distribution. Instead of just identifying what binds to muscle, we quantify how much less it binds to the heart vs. skeletal muscle, providing a level of granularity essential for precision medicine.

Strategic Advantages of Creative Biolabs

Diverse Animal Models: Capability to perform screening in mice, rats, NHP, or disease-specific transgenic models.
Tissue-Specific Resolution: We can distinguish between "fast-twitch" and "slow-twitch" muscle homing.
End-to-End Integration: From library construction to lead optimization and peptide-drug conjugate (PDC) development.
AI Ready Content: Our data-driven reports are formatted for easy integration into digital research ecosystems and AI-driven drug discovery pipelines.

Explore Our Comprehensive Services

To further your research, consider our integrated In Vivo Phage Library Screening Services modules:

Learn more about other Phage Display Library Screening Services:

Creative Biolabs is dedicated to accelerating your musculoskeletal research. Our Muscle Targeting In Vivo Phage Library Screening Service provides the high-resolution data needed to turn a systemic drug into a precision-guided therapeutic.

Contact our experts today to design your customized in vivo screening project.

Contact Us Today for a Free Quote!

Frequently Asked Questions (FAQs)

Q: Can you target specific muscle types, such as the myocardium?
A: Yes, we offer specialized Cardiac Muscle Homing services where the phage recovery is focused exclusively on the heart tissue, including counter-selection against skeletal muscle.
Q: How do you ensure the peptides identified are not just binding to the blood vessels within the muscle?
A: We use a rigorous systemic perfusion protocol with saline or PBS before tissue harvesting to wash away phages that are loosely associated with the endothelium or still in the blood.
Q: What is the advantage of using NGS over traditional Sanger sequencing for phage display?
A: NGS allows us to analyze millions of sequences, enabling us to see the "enrichment trajectory" of a clone across rounds, even if it is not the dominant clone, often revealing highly specific but lower-abundance binders.
Q: Can the identified peptides be used for AAV capsid engineering?
A: Absolutely. Many of our clients use the peptides discovered through our in vivo screening to modify the loops of AAV capsids for muscle-tropic gene therapy.
Q: Are the peptides discovered stable in human serum?
A: While screening is done in animal models, we provide downstream peptide modification services (e.g., D-amino acid substitution or cyclization) to enhance proteolytic stability for human applications.
Q: What quantity of phage library is injected?
A: Generally, we inject 10¹¹ to 10¹³ plaque-forming units (pfu) to ensure adequate coverage of the library's diversity within the animal's circulation.
Q: Does Creative Biolabs provide help with the functional validation of the hits?
A: Yes, we offer in vitro binding assays (ELISA, Flow Cytometry) and in vivo biodistribution studies using labeled peptides to confirm the screening results.
Q: What animal models are available for muscle targeting screening?
A: We primarily use mice and specialized disease models like mdx mice for DMD. Large animal models (e.g., rabbits or non-human primates) can be accommodated upon request.
Q: How many rounds of biopanning are typically required?
A: Usually 3 to 4 rounds. This allows for sufficient enrichment of specific binders while maintaining the diversity of potential lead candidates.
Q: Is NGS mandatory for this service?
A: While optional, we highly recommend it. NGS provides a much deeper view of the library's evolution and can identify potent peptides that might be missed by traditional colony picking.
Q: What is the typical length of the peptides in your libraries?
A: Our standard libraries display 7-mer to 12-mer peptides. Longer or constrained (cyclic) peptides are also available.
Q: Do you provide the physical phage clones at the end of the project?
A: Yes, we provide the enriched library pool, individual validated clones, and a comprehensive sequencing report.
Q: How do you validate the "tissue-penetrating" ability?
A: We use a combination of microdialysis-based recovery and immunofluorescence microscopy to confirm that the phages have moved from the vasculature into the extravascular muscle tissue.

Reference

Pemmari, Toini, et al. "Screening of homing and tissue-penetrating peptides by microdialysis and in vivo phage display." Life science alliance 8.5 (2025). https://doi.org/10.26508/lsa.202201490

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.